Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Ulaanbaatar, Mongolia Clinical Trials

A listing of Ulaanbaatar, Mongolia clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L

Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma. The results will be compared to placebo. The trial duration is 3 months and will consist of one stage with baseline laboratory evaluation including AFP levels with follow-up at ...

Phase

0.0 miles

Learn More »

Open Label Trial of Immunotherapy for Advanced Liver Cancer

Hepcortespenlisimut-L (V5) immunotherapy of HCC in an open label setting with baseline alphafetoprotein serum levels and CT scan image as primary endpoints with monthly follow-up thereafter. Additional endpoints will include blood biochemistry indices and safety monitoring.

Phase

0.0 miles

Learn More »

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer

This study is an open label Phase II study aimed to recruit at least 20 patients with inoperable PDA and who are positive for CA19.9 pancreatic tumor marker. The presence of higher than normal levels of CA19.9 is the sole inclusion criteria. Patients will be given one tablet of V3-P ...

Phase

0.0 miles

Learn More »

The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)

The purpose of the study is to test whether the health care provider access and training in CERTAIN (Checklist for Early Recognition and Treatment of Acute Illness), would facilitate timely and error free best-practice delivery and minimize preventable death and costly complications in critically ill patients.

Phase N/A

0.0 miles

Learn More »

Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Upon obtaining regulatory and ethical approvals the Phase II single-arm study will be initiated at the NCC involving 20 patients with confirmed CCA diagnosis. The trial will be short, it will last only 2 months, but this will be sufficient to gauge the safety and efficacy. Only those patients who ...

Phase

0.0 miles

Learn More »

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

The STREAM study is an international, multi-centre, parallel-group, open-label, randomised, controlled trial in patients with multi-drug resistant tuberculosis (MDR-TB) including patients with rifampicin-resistant and isoniazid-sensitive TB. Background and Rationale: The current recommended treatment approach for MDR-TB is based largely on expert opinion and there is a lack of good evidence ...

Phase

0.0 miles

Learn More »

Open Label Immunotherapy of Myoma

Myoma or uterine fibroids are one of the most common gynecological diseases, which occurs in at least one third of women older than 35 years, and after 40 - in every second. We will test a new tablet preparation, V3-Myoma, obtained from hydrolyzed, inactivated blood and tumor tissues of patients ...

Phase

0.0 miles

Learn More »

Immunotherapy of Cervical Cancer With V3-Cervix

Cervical cancer (CC) is a malignant neoplasm that occurs in the cervix. Histologically, there are two main types: adenocarcinoma and squamous cell carcinoma. Cervical cancer is most common in middle-aged women (35-55 years of age), in 20% of cases it is found over the age of 65 years. Cancer of ...

Phase

0.0 miles

Learn More »

Open Label Immunotherapy Trial for Ovarian Cancer

Ovarian cancer (OC) - a malignant disease affecting the ovarian tissue - is the sixth most diagnosed cancer among women and causes more deaths than any other cancer of the female reproductive system. For treatment of OC, surgical intervention, chemotherapy, as well as radiation methods are used. Despite treatment, about ...

Phase

0.0 miles

Learn More »

Open Label Immunotherapy Trial for Breast Cancer

Worldwide, breast cancer is the number one cancer in women. It affects about 12% or 1.7 mln women worldwide. In Mongolia breast cancer is less common, occupies 5-th place by frequency in women, the incidence is 118 per 100,000 or 1,770 cases per year. Many different types of immunotherapy (especially ...

Phase

0.0 miles

Learn More »